Peptide inhibitors of dengue virus and West Nile virus infectivity

Viral fusion proteins mediate cell entry by undergoing a series of conformational changes that result in virion-target cell membrane fusion. Class I viral fusion proteins, such as those encoded by influenza virus and human immunodeficiency virus (HIV), contain two prominent alpha helices. Peptides that mimic portions of these alpha helices inhibit structural rearrangements of the fusion proteins and prevent viral infection. The envelope glycoprotein (E) of flaviviruses, such as West Nile virus (WNV) and dengue virus (DENV), are class II viral fusion proteins comprised predominantly of beta sheets. We used a physio-chemical algorithm, the Wimley-White interfacial hydrophobicity scale (WWIHS) [1] in combination with known structural data to identify potential peptide inhibitors of WNV and DENV infectivity that target the viral E protein. Viral inhibition assays confirm that several of these peptides specifically interfere with target virus entry with 50% inhibitory concentration (IC50) in the 10 μM range. Inhibitory peptides similar in sequence to domains with a significant WWIHS scores, including domain II (IIb), and the stem domain, were detected. DN59, a peptide corresponding to the stem domain of DENV, inhibited infection by DENV (>99% inhibition of plaque formation at a concentrations of <25 μM) and cross-inhibition of WNV fusion/infectivity (>99% inhibition at <25 μM) was also demonstrated with DN59. However, a potent WNV inhibitory peptide, WN83, which corresponds to WNV E domain IIb, did not inhibit infectivity by DENV. Additional results suggest that these inhibitory peptides are noncytotoxic and act in a sequence specific manner. The inhibitory peptides identified here can serve as lead compounds for the development of peptide drugs for flavivirus infection.

[1]  R. Compans,et al.  Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. , 1996, Virology.

[2]  A. Barrett Current Status of Flavivirus Vaccines , 2001, Annals of the New York Academy of Sciences.

[3]  J. Sodroski HIV-1 Entry Inhibitors in the Side Pocket , 1999, Cell.

[4]  J. Lang,et al.  Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. , 2002, The American journal of tropical medicine and hygiene.

[5]  D. Vaughn,et al.  Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. , 2001, Vaccine.

[6]  Y. Modis,et al.  Structure of the dengue virus envelope protein after membrane fusion , 2004, Nature.

[7]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Samuel K Sia,et al.  Short constrained peptides that inhibit HIV-1 entry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Marks,et al.  Demonstration of binding of dengue virus envelope protein to target cells , 1996, Journal of virology.

[10]  Y. Modis,et al.  A ligand-binding pocket in the dengue virus envelope glycoprotein , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  A. Barrett,et al.  Solution Structure and Antibody Binding Studies of the Envelope Protein Domain III from the New York Strain of West Nile Virus* , 2004, Journal of Biological Chemistry.

[12]  H. Kida,et al.  A synthetic peptide from a heptad repeat region of herpesvirus glycoprotein B inhibits virus replication. , 2004, The Journal of general virology.

[13]  H. Bultmann,et al.  Peptides Containing Membrane-transiting Motifs Inhibit Virus Entry* , 2002, Journal of Biological Chemistry.

[14]  J. Lepault,et al.  Conformational change and protein–protein interactions of the fusion protein of Semliki Forest virus , 2004, Nature.

[15]  C. Mandl,et al.  Mapping of Functional Elements in the Stem-Anchor Region of Tick-Borne Encephalitis Virus Envelope Protein E , 1999, Journal of Virology.

[16]  R. Edelman,et al.  Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. , 2003, The American journal of tropical medicine and hygiene.

[17]  B. Wold,et al.  Know Your Neighbors: Three Phenotypes in Null Mutants of the Myogenic bHLH Gene MRF4 , 1996, Cell.

[18]  Shinji Watanabe,et al.  Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein , 2000, Journal of Virology.

[19]  M. Rossmann,et al.  A structural perspective of the flavivirus life cycle , 2005, Nature Reviews Microbiology.

[20]  F. Rey,et al.  Dengue virus envelope glycoprotein structure: New insight into its interactions during viral entry , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. King,et al.  Analysis of the steps involved in Dengue virus entry into host cells. , 1999, Virology.

[22]  Y. Shai,et al.  A synthetic peptide corresponding to a conserved heptad repeat domain is a potent inhibitor of Sendai virus‐cell fusion: an emerging similarity with functional domains of other viruses. , 1995, The EMBO journal.

[23]  B. Guy,et al.  Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. , 2004, Vaccine.

[24]  Chris Doane,et al.  Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus , 2005, Nature Medicine.

[25]  T. Morrison,et al.  Interaction of Peptides with Sequences from the Newcastle Disease Virus Fusion Protein Heptad Repeat Regions , 1999, Journal of Virology.

[26]  S. Halstead,et al.  Pathogenesis of dengue: challenges to molecular biology. , 1988, Science.

[27]  R. Garry,et al.  Theoretical Biology and Medical Modelling Open Access Proteomics Computational Analyses Suggest That the Carboxyl Terminal Glycoproteins of Bunyaviruses Are Class Ii Viral Fusion Protein (beta-penetrenes) Viral Fusion Proteinsbunyavirus Envelope Glycoproteinsproteomics Computational Analysesglycopro , 2022 .

[28]  Suh-Chin Wu,et al.  Structural Basis of a Flavivirus Recognized by Its Neutralizing Antibody , 2003, Journal of Biological Chemistry.

[29]  A. Barrett,et al.  Identification of Neutralizing Epitopes within Structural Domain III of the West Nile Virus Envelope Protein , 2002, Journal of Virology.

[30]  F. Guirakhoo,et al.  Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates , 2004, Journal of Virology.

[31]  P. S. Kim,et al.  A spring-loaded mechanism for the conformational change of influenza hemagglutinin , 1993, Cell.

[32]  M. Pistello,et al.  The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. , 2004, Virology.

[33]  D. Coy,et al.  Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. , 1990, AIDS.

[34]  Wei Zhang,et al.  Structure of Dengue Virus Implications for Flavivirus Organization, Maturation, and Fusion , 2002, Cell.

[35]  R. Garry,et al.  A general model for the transmembrane proteins of HIV and other retroviruses. , 1989, AIDS research and human retroviruses.

[36]  Duane J. Gubler,et al.  Dengue and Dengue Hemorrhagic Fever , 1998, Clinical Microbiology Reviews.

[37]  N. Bhamarapravati,et al.  Live attenuated tetravalent dengue vaccine. , 2000, Vaccine.

[38]  M. Saeed,et al.  Dengue and Dengue Hemorrhagic Fever , 2015 .

[39]  D. Vaughn,et al.  Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. , 2003, The American journal of tropical medicine and hygiene.

[40]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[41]  Stephen H. White,et al.  Experimentally determined hydrophobicity scale for proteins at membrane interfaces , 1996, Nature Structural Biology.

[42]  Bong-Suk Kim,et al.  Structure of West Nile Virus , 2003, Science.

[43]  R. Edelman,et al.  Atypical antibody responses in dengue vaccine recipients. , 2003, The American journal of tropical medicine and hygiene.

[44]  W. Gallaher,et al.  Similar Structural Models of the Transmembrane Proteins of Ebola and Avian Sarcoma Viruses , 1996, Cell.

[45]  T. Matthews,et al.  A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.

[46]  B. Bosch,et al.  The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex , 2003, Journal of Virology.

[47]  G. Melikyan,et al.  A study of low pH-induced refolding of Env of avian sarcoma and leukosis virus into a six-helix bundle. , 2004, Biophysical journal.

[48]  H. Hotta,et al.  Enhancement of Dengue Virus Infection in Cultured Mouse Macrophages by Lipophilic Derivatives of Muramyl Peptides , 1985, Microbiology and immunology.

[49]  F. Guirakhoo,et al.  Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. , 2002, Virology.

[50]  K. Stiasny,et al.  Structure of a flavivirus envelope glycoprotein in its low‐pH‐induced membrane fusion conformation , 2004, The EMBO journal.

[51]  S. Watowich,et al.  Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope Protein , 2001, Journal of Virology.

[52]  R. Garry,et al.  Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. , 2003, Virology.

[53]  Ying Zhang,et al.  Structures of immature flavivirus particles , 2003, The EMBO journal.

[54]  D. Lambert,et al.  Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Navaza,et al.  The Fusion Glycoprotein Shell of Semliki Forest Virus An Icosahedral Assembly Primed for Fusogenic Activation at Endosomal pH , 2001, Cell.

[56]  S. Harrison,et al.  The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution , 1995, Nature.

[57]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.